Solid Tumor Study Investigating Ibrutinib (IMBRUVICAÂ®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers